EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Flecainide in structural heart diseases: A contemporary reappraisal beyond the CAST

Davide Genovese, Michael Salama, Donatella Ruggiero, Giuseppe Sgarito, Pietro Francia, Francesco Santoro, Laura Perrotta, Giacomo Mugnai

Heart Rhythm · 2026-08 · 23 (8) · 1661-1668

DOI: 10.1016/j.hrthm.2025.08.034 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Heart Rhythm, 2026-08. Verfasst von Davide Genovese und 7 weiteren Autor:innen. Beteiligte Einrichtung: Cardiology Unit, Cardio-Neuro-Vascular Department, Ca' Foncello Hospital, Treviso, Italy. Electronic address: genovesedavide@outlook.com. Hauptthemen laut MEDLINE: Flecainide. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 64 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Flecainide has been contraindicated in patients with structural heart disease since the 1991 Cardiac Arrhythmia Suppression Trial showed increased mortality in post-myocardial infarction patients. This review argues that the Cardiac Arrhythmia Suppression Trial findings were overgeneralized, resulting in the underutilization of a valuable antiarrhythmic medication. Emerging observational evidence suggests that flecainide may be safe and effective in specific structural heart disease populations, including those with stable coronary artery disease without active ischemia and preserved ventricular function. Its use also shows promise in various cardiomyopathies (CMs) such as arrhythmogenic right ventricular CM and premature ventricular complex-induced CM, supporting a nuanced, patient-specific approach that challenges existing flecainide safety dogma and moves beyond outdated misconceptions. Randomized controlled trials are needed to confirm the recent observational findings and redefine the role of flecainide in contemporary cardiology.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

FlecainideHumansAnti-Arrhythmia Agents

Stichwörter der Autor:innen

CardiomyopathyClass IC antiarrhythmicsFlecainideIschemic heart diseaseStructural heart diseaseVentricular arrhythmias

Substanzen

FlecainideAnti-Arrhythmia Agents

Autor:innen und Institutionen

  • Cardiology Unit, Cardio-Neuro-Vascular Department, Ca' Foncello Hospital, Treviso, Italy. Electronic address: genovesedavide@outlook.com.
  • Cardiology Unit, Cardio-Neuro-Vascular Department, Ca' Foncello Hospital, Treviso, Italy.
  • Ospedale Pio XI, Desio, MB, Italy.
  • Istituto di Ricovero e Cura a Carattere Scientifico Istituto Mediterraneo Trapianto e Terapia ad alta Specializzazione, UPMC Palermo, Palermo, Italy.
  • Cardiology, Department of Clinical and Molecular Medicine, Sant'Andrea Hospital, University Sapienza, Rome, Italy.
  • Department of Medical and Surgical Sciences, University of Foggia, Foggia, Italy.

Zitieren

APA

Genovese, D., Salama, M., Ruggiero, D., Sgarito, G., Francia, P., Santoro, F., Perrotta, L., & Mugnai, G. (2026). Flecainide in structural heart diseases: A contemporary reappraisal beyond the CAST. Heart Rhythm, 23(8), 1661-1668. https://doi.org/10.1016/j.hrthm.2025.08.034

Vancouver

Genovese D, Salama M, Ruggiero D, Sgarito G, Francia P, Santoro F, et al. Flecainide in structural heart diseases: A contemporary reappraisal beyond the CAST. Heart Rhythm. 2026;23(8):1661-1668. doi:10.1016/j.hrthm.2025.08.034

BibTeX
@article{Genovese2026,
  author = {Genovese, Davide and Salama, Michael and Ruggiero, Donatella and Sgarito, Giuseppe and Francia, Pietro and Santoro, Francesco and Perrotta, Laura and Mugnai, Giacomo},
  title = {Flecainide in structural heart diseases: A contemporary reappraisal beyond the CAST},
  journal = {Heart Rhythm},
  year = {2026},
  volume = {23},
  number = {8},
  pages = {1661--1668},
  doi = {10.1016/j.hrthm.2025.08.034}
}
Kostenlos starten →